Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in Localized dMMR/MSI-H Colon Cancer
NCT06646445Phase 2Not yet recruiting
- Sponsor
- GERCOR
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by GERCOR. Primary endpoint: Rate of success of the experimental strategy at 6 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06646445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646445.